Yana Najjar, MD

Articles by Yana Najjar, MD

Yana Najjar, MD, discusses phase 1/1b STEALTH-001 data for the oncolytic virus VET3-TGI in advanced solid tumors, including cutaneous cancers.

Dr Najjar on Data for the Oncolytic Virus VET3-TGI in Advanced Solid Tumors

ByYana Najjar, MD

November 6th 2026

Yana Najjar, MD, discusses phase 1/1b STEALTH-001 data for the oncolytic virus VET3-TGI in advanced solid tumors, including cutaneous cancers.

Latest Updated Articles

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026

LITESPARK-012, XmAb819, and PE-PE Data Headline Key Kidney Cancer Findings From ESMO 2026